{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T01:39:47Z","timestamp":1755999587068,"version":"3.41.0"},"reference-count":34,"publisher":"Japan Endocrine Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej24-0727","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T22:11:41Z","timestamp":1741644701000},"page":"781-789","source":"Crossref","is-referenced-by-count":1,"title":["Status of temozolomide use without insurance coverage in patients with aggressive pituitary neuroendocrine tumors"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3492-4845","authenticated-orcid":false,"given":"Atsushi","family":"Ishida","sequence":"first","affiliation":[{"name":"Hypothalamic &amp; Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-3388","authenticated-orcid":false,"given":"Naoko","family":"Inoshita","sequence":"additional","affiliation":[{"name":"Department of Pathology, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Shiramizu","sequence":"additional","affiliation":[{"name":"Hypothalamic &amp; Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruko","family":"Yoshimoto","sequence":"additional","affiliation":[{"name":"Hypothalamic &amp; Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Kato","sequence":"additional","affiliation":[{"name":"Hypothalamic &amp; Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0417-1432","authenticated-orcid":false,"given":"Go","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Hypothalamic &amp; Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shozo","family":"Yamada","sequence":"additional","affiliation":[{"name":"Hypothalamic &amp; Pituitary Center, Moriyama Memorial Hospital, Tokyo 134-0081, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, et al. (2022) Clinical biology of the pituitary adenoma. Endocr Rev 43: 1003\u20131037.","DOI":"10.1210\/endrev\/bnac010"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Nishioka H (2023) Aggressive pituitary tumors (PitNETs). Endocr J 70: 241\u2013248.","DOI":"10.1507\/endocrj.EJ23-0007"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, et al. (2022) Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J Endocrinol 187: 593\u2013605.","DOI":"10.1530\/EJE-22-0440"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ng S, Messerer M, Engelhardt J, Bruneau M, Cornelius JF, et al. (2021) Aggressive pituitary neuroendocrine tumors: current practices, controversies, and perspectives, on behalf of the EANS skull base section. Acta Neurochir (Wien) 163: 3131\u20133142.","DOI":"10.1007\/s00701-021-04953-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Iglesias P (2023) Aggressive and metastatic pituitary neuroendocrine tumors: therapeutic management and off-label drug use. J Clin Med 13: 116.","DOI":"10.3390\/jcm13010116"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Burman P, Lamb L, McCormack A (2020) Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives. Rev Endocr Metab Disord 21: 263\u2013276.","DOI":"10.1007\/s11154-020-09551-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Nakano-Tateno T, Lau KJ, Wang J, McMahon C, Kawakami Y, et al. (2021) Multimodal non-surgical treatments of aggressive pituitary tumors. Front Endocrinol (Lausanne) 12: 624686.","DOI":"10.3389\/fendo.2021.624686"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Syro LV, Rotondo F, Camargo M, Ortiz LD, Serna CA, et al. (2018) Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions. Front Endocrinol (Lausanne) 9: 318.","DOI":"10.3389\/fendo.2018.00318"},{"key":"9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12885-024-11926-2","volume":"24","author":"E Taherifard","year":"2024","unstructured":"9 Taherifard E, Bakhtiar M, Mahnoor M, Ahmed R, Cavalcante L, et al. (2024) Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis. BMC Cancer 24: 192.","journal-title":"BMC Cancer","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2407","issn-type":"print"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 \u00dcnal \u00c7, Azizy A, Karabulut S, Ta\u015ftekin D, Aky\u0131ld\u0131z A, et al. (2023) Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: data from the Turkish oncology group. Oncologist 28: 875\u2013884.","DOI":"10.1093\/oncolo\/oyad257"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Elbelt U, Schlaffer SM, Buchfelder M, Knappe UJ, Vila G, et al. (2020) Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-a german survey. J Clin Endocrinol Metab 105: dgz211.","DOI":"10.1210\/clinem\/dgz211"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Zacharia BE, Gulati AP, Bruce JN, Carminucci AS, Wardlaw SL, et al. (2014) High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 74: E447\u2013E455; discussion E455.","DOI":"10.1227\/NEU.0000000000000251"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Nakano-Tateno T, Satou M, Inoshita N, van Landeghem FKH, Easaw J, et al. (2021) Effects of CAPTEM (capecitabine and temozolomide) on a corticotroph carcinoma and an aggressive corticotroph tumor. Endocr Pathol 32: 418\u2013426.","DOI":"10.1007\/s12022-020-09647-w"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kim HJ, Shin SW, Song EK, Lee NR, Kim JS, et al. (2015) Ramosetron <i>versus<\/i> ondansetron in combination with aprepitant and dexamethasone for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: a multicenter, randomized phase III trial, KCSG PC10-21. Oncologist 20: 1440\u20131447.","DOI":"10.1634\/theoncologist.2015-0128"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Ko CC, Yeh LR, Kuo YT, Chen JH (2021) Imaging biomarkers for evaluating tumor response: RECIST and beyond. Biomark Res 9: 52.","DOI":"10.1186\/s40364-021-00306-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Janssen JM, Jacobs BAW, Roosendaal J, Derissen EJB, Marchetti S, et al. (2021) Population pharmacokinetics of intracellular 5-fluorouridine 5&apos;-triphosphate and its relationship with hand-and-foot syndrome in patients treated with capecitabine. AAPS J 23: 23.","DOI":"10.1208\/s12248-020-00533-1"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, et al. (2015) The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 26: 349\u2013355.","DOI":"10.1007\/s12022-015-9398-z"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Losa M, Bogazzi F, Cannavo S, Ceccato F, Curt\u00f2 L, et al. (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neurooncol 126: 519\u2013525.","DOI":"10.1007\/s11060-015-1991-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, et al. (2018) Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol 178: 265\u2013276.","DOI":"10.1530\/endoabs.49.OC12.2"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Lamas C, C\u00e1mara R, Fajardo C, Remon-Ruiz P, Biagetti B, et al. (2023) Efficacy and safety of temozolomide in the treatment of aggressive pituitary neuroendocrine tumours in Spain. Front Endocrinol (Lausanne) 14: 1204206.","DOI":"10.3389\/fendo.2023.1204206"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Minniti G, Paolini S, Rea MLJ, Isidori A, Scaringi C, et al. (2020) Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas. J Neurooncol 149: 123\u2013130.","DOI":"10.1007\/s11060-020-03579-5"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Zhang J, Stevens MF, Bradshaw TD (2012) Temozolomide: mechanisms of action, repair and resistance. Curr Mol Pharmacol 5: 102\u2013114.","DOI":"10.2174\/1874467211205010102"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, et al. (2023) Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J Clin Oncol 41: 1359\u20131369.","DOI":"10.1200\/JCO.22.01013"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Ishida A, Shichi H, Fukuoka H, Inoshita N, Ogawa W, et al. (2022) Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay. Pituitary 25: 238\u2013245.","DOI":"10.1007\/s11102-021-01192-x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Ishida A, Shichi H, Fukuoka H, Shiramizu H, Inoshita N, et al. (2022) Temozolomide and capecitabine treatment for an aggressive somatotroph pituitary tumor: a case report and literature review. Front Oncol 12: 916982.","DOI":"10.3389\/fonc.2022.916982"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26 Thearle MS, Freda PU, Bruce JN, Isaacson SR, Lee Y, et al. (2011) Temozolomide (Temodar<sup>\u00ae<\/sup>) and capecitabine (Xeloda<sup>\u00ae<\/sup>) treatment of an aggressive corticotroph pituitary tumor. Pituitary 14: 418\u2013424.","DOI":"10.1007\/s11102-009-0211-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Donovan LE, Arnal AV, Wang SH, Odia Y (2016) Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy. CNS Oncol 5: 203\u2013209.","DOI":"10.2217\/cns-2016-0011"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Joehlin-Price AS, Hardesty DA, Arnold CA, Kirschner LS, Prevedello DM, et al. (2017) Case report: ACTH-secreting pituitary carcinoma metastatic to the liver in a patient with a history of atypical pituitary adenoma and Cushing\u2019s disease. Diagn Pathol 12: 34.","DOI":"10.1186\/s13000-017-0624-5"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Lin AL, Jonsson P, Tabar V, Yang TJ, Cuaron J, et al. (2018) Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab. J Clin Endocrinol Metab 103: 3925\u20133930.","DOI":"10.1210\/jc.2018-01347"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Mirallas O, Filippi-Arriaga F, Hernandez Hernandez I, Aubanell A, Chaachou A, et al. (2021) Aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson\u2019s syndrome: a case report. Front Endocrinol (Lausanne) 12: 731631.","DOI":"10.3389\/fendo.2021.731631"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Das L, Rai A, Salunke P, Ahuja CK, Sood A, et al. (2022) Temozolomide nonresponsiveness in aggressive prolactinomas and carcinomas: management and outcomes. J Endocr Soc 6: bvab190.","DOI":"10.1210\/jendso\/bvab190"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Bengtsson D, Schr\u00f8der HD, Andersen M, Maiter D, Berinder K, et al. (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100: 1689\u20131698.","DOI":"10.1210\/jc.2014-4350"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Wang X, Hu C, Li Y, Ren B, Yin G (2022) Chemotherapy of capecitabine plus temozolomide for refractory pituitary adenoma after tumor resection and its impact on serum prolactin, IGF-1, and growth hormone. J Oncol 2022: 8361775.","DOI":"10.1155\/2022\/8361775"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Burman P, Casar-Borota O, Perez-Rivas LG, Dekkers OM (2023) Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment. J Clin Endocrinol Metab 108: 1585\u20131601.","DOI":"10.1210\/clinem\/dgad098"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/7\/72_EJ24-0727\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:32:36Z","timestamp":1751686356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/7\/72_EJ24-0727\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej24-0727","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ24-0727"}}